BioPharm International, October 2004 - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

BioPharm International, October 2004
Manufacturing
Modular Construction: Innovation, Flexibility, and Adaptibility by Design
By John R. Rydall
Identifying issues in the factory that traditionally arise in the field minimized onsite equipment rework and subsequent qualification work.
Manufacturing Vaccines for the Developing World
By Donald F. Gerson , Bhawani Mukherjee
A handful of facilities making 200 million single-dose units per year could fast-track the immunization of the developing world.
Bioequivalence
Gastric-State-Controlled Bioequivalence Studies
By Nasir M. Idkaidek, Ph.D. , Naji Najib, Ph.D. , Ahmad Al-Ghazawi, PhD
Establishing bioequivalence is difficult for drugs with high inter-subject variability or strong dependence on the physiological state of the gut.
Quality
Supply Chain Cycle Time Reduction
By Allen Jacques
Wyeth BioPharma has identified cycle-time reduction as critical to customer responsiveness and the success of commercial and pipeline products. In formulating a plan of attack, the company focused on two aspects of cycle time: the global planning process and disposition cycle times.
Validation
Validating Analytical Methods for Biopharmaceuticals, Part 1: Development and Optimization
By Stephan Krause, PhD
The relationship between "valid" or "suitable and validated" is often overlooked, but there is a high price when "validated" test systems are simply inappropriate.
International BioMarket
Biotech Industry Finds Fertile Ground in the Netherlands
Though still relatively modest by international standards, the Netherlands' biotechnology industry has made impressive gains in recent years and now provides investors with a compelling alternative to more established European "heavyweights" such as Scandinavia, Switzerland, and the United Kingdom.
Columns and Departments
Editorial—Where's the Money?
By Carol L. Fisher
Let's be frank. Love doesn't make the world go round —money does, especially if you're developing a promising technology but you're facing ten or fifteen more years of bench time and clinical trials before you can unveil a marketable product.
StreetTalk: Corporate Wellness Programs
By Brian O'Connell
We've gone beyond the days when corporate America's idea of a healthy outing was a company softball game complete with beer and hot dogs.
Regulatory Beat: Pharmacogenomics Discoveries Shape Biotech R&D
By Jill Wechsler
Even if FDA does not require pharma companies to co-market a diagnostic test, insurers and health plans may pressure industry to do so, according to Robert Temple of CDER.
Final Word: Riding on the Coattails of US Patients
By Merrill Matthews, Ph.D.
In general, people in other countries pay less for brand-name prescription drugs than people in the US. As a result, some Americans travel to Canada or Mexico to get their prescriptions, and an increasing number are using the Internet to buy drugs from other countries.

ADVERTISEMENT

ADVERTISEMENT

Click here